Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 28, 2015

View Archived Issues

ChemoCentryx, a company focusing on chemoattractant receptors, reviews company outlook

Novel synthetic medium-size compounds mimic functions of antibodies

New evidence provided on SEMA4D as a promising target for MS

3SBio acquires contract manufacturer Sirton Pharmaceuticals

PXT-864 pleodrug improves biological AD-related features

RestorGenex compound granted FDA orphan status for glioblastoma multiforme

Aclaris Therapeutics reports data from phase IIb trial of A-101

Actavis to acquire Auden Mckenzie

Hybrigenics extends partnership with Servier for ubiquitin-specific protease inhibitors

Pfizer aims to improve access to Prevenar 13 in poorest countries

Redx Pharma patents Hedgehog signaling pathway inhibitors

Takeda reports development of RORgamma-t antagonists

Anti-IL-32 MAbs described in ImmunoQure patent

Academic researchers prepare and test ALK inhibitors

Abide Therapeutics divulges MGL inhibitors

National University of Singapore presents peptide inhibitors of FXI

NRX-1074 improves depression scores in phase I study

CF-602 shows promise for sexual dysfunction in preclinical studies

Cutanea Life Sciences initiates phase II trial of CLS-003 for cutaneous warts

PlantForm initiates financing round to fund development of biosimilars

Boehringer Ingelheim studies effect of tiotropium and olodaterol Respimat on COPD exacerbations

Forest initiates pediatric phase I/II trial of ceftaroline fosamil

Radius Health initiates phase I trial of RAD-1901 in breast cancer

Amgen and Onyx file applications to expand approval of carfilzomib in the E.U. and U.S.

Janssen closes collaboration and license agreement with MacroGenics for MGD-011

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 26, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...
Muted and missing M&As: JPM deals absent in 2026
BioWorld
For years, the J.P. Morgan Healthcare Conference (JPM) kicked off with splashy headlines of major M&A activity among biopharma companies, but in 2026, the hype...
Sumitomo’s DSP-3456 exerts antidepressant-like effects
BioWorld Science
About one-third of patients with major depressive disorder (MDD) are treatment resistant. Ketamine is very effective in treatment-resistant depression, but it is...